We aimed to compare the cytogenetic and molecular analyses in the assessment of imatinib
mesylate response in patients suffering the chronic phase of chronic myelocytic leukemia …

Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …

CML patients who obtain a complete cytogenetic response (CCgR) may harbor different
degrees of molecular disease, which are associated with different progression-free survival …

Purpose: To determine the clinical significance of molecular response and relapse among
patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental …

Background Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …

We studied 94 clinically heterogeneous chronic myeloid leukemia (CML) patients and found
that the duration of treatment with interferon-alpha (IFN-alpha) prior to imatinib therapy may …

Most patients (pts) with CML in chronic phase treated with imatinib achieve a major
cytogenetic (CG) remission, and increasing numbers of pts are achieving molecular …

BACKGROUND. Response rates in chronic myeloid leukemia (CML) are now reported
based on the cumulative incidence of a single‐time best response. The study aim was to …

Cytogenetic and molecular responses to standard-dose imatinib (IM) were correlated with
trough IM plasma levels for 78 patients with chronic myeloid leukemia (CML) after a …

Purpose: The achievement of a major molecular response (MMolR) at 12 months is a
surrogate marker of progression-free survival in chronic myeloid leukemia patients treated …